Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Vaccine price increases are leading House Ways & Means/Health Subcommittee Chairman Stark (D-Calif.) to "question" the need for manufacturer R&D tax credits, according to subcommittee staffers. In a Jan. 9 press release, the California Democrat observed that diphtheria-pertussis-tetanus (DPT) vaccine prices have increased 6,950% during the last decade. He also pointed out that the price of the measles-mumps-rubella (MMR) vaccine has also increased significantly. Stark's press release notes that a DPT vaccination that cost 12 in 1980 now costs $8.46, while the cost of an MMR vaccination has jumped from $2.71 in 1980 to $16.18. However, some of that price increase was created by Congress, which in 1986 enacted a federally insured childhood vaccine injury program. A tax collected on each marketed vaccine dose goes into a trust fund for compensating children injured by adverse reactions to the vaccine products. "The profits made by the pharmaceutical companies on these vaccines are not public knowledge, [so] we do not know, and cannot know, whether the companies are making a respectable and conscionable profit or an outrageous and irresponsible profit," Stark said. "Before Congress extends tax breaks again in September for the drug manufacturers, we should get an explanation of this insane price inflation and a commitment to work together for better health for all Americans." Congress extended R&D tax credits through September 1990 in the Omnibus Budget Reconciliation Act of 1989, signed into law Dec. 19. The credits likely will be considered again this year during the budget reconciliation process. Staffers said that Stark has not yet approached either industry or federal agencies about the vaccine price issue. * Last spring, Stark wrote a "Dear Colleague" letter to counter drug industry lobbying for the tax credit. He contended that "an industry whose net profit margin is consistently twice that of industry as a whole" should not be subsidized through tax credits ("The Pink Sheet" April 10, p. 12). "Even if you don't have children, you are paying for this inflation through your taxes," Stark continued. "We are all paying through tax breaks for the pharmaceutical companies, through support of public clinics overburdened with families unable to afford the price of the vaccines, and by taxes to pay for sick children too poor to afford insurance." He noted that there have been increases in cases of mumps, measles and rubella because some parents cannot afford to have their children vaccinated.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts